Standard Document
Third Edition
Microbiology

CLSI M27M44S

Performance Standards for Antifungal Susceptibility Testing of Yeasts

This document provides updated minimal inhibitory concentration (MIC), zone diameter, and quality control (QC) tables for use with CLSI antifungal susceptibility testing standards. These updates ensure laboratories have the most current breakpoints and guidelines for accurate and standardized antifungal susceptibility testing.

August 03, 2022
Gary W. Procop, MD, MS

{{FormatPrice(currentPrice)}}

Free

{{FormatPrice(nonMemberPrice)}} List Price
This is your member pricing.
Notify Me About New Editions
Abstract

Clinical and Laboratory Standards Institute document M27M44S—Performance Standards for Antifungal Susceptibility Testing of Yeasts includes minimal inhibitory concentration, zone diameter, and quality control tables developed following the guidance in CLSI documents M27 and M44.(2) The data in the tables are valid only when the methodologies in CLSI documents M27 and M44 are followed. Users should replace previously published tables with these new tables. Changes in the tables since the previous edition was published appear in boldface type.

Overview of Changes

This document replaces the previous edition of the approved document, M60-Ed2, published in 2020. Several changes were made in this edition.

Product Details
M27M44SEd3E
978-1-68440-163-5
40
Additional Details

The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.

Authors
Gary W. Procop, MD, MS
Philippe J. Dufresne, PhD, RMCCM
Elizabeth Berkow, PhD
Sharon K. Cullen, BS, RAC
Tanis Dingle, PhD, D(ABMM), FCCM
Jeff Fuller, PhD, FCCM, D(ABMM)
Kimberly E. Hanson, MD, MHS
Nicole M. Holliday, BA
Audrey N. Schuetz, MD, MPH, D(ABMM)
Paul E. Verweij, MD, FECMM
Nathan P. Wiederhold, PharmD
Adrian M. Zelazny, PhD, D(ABMM)
Abstract

Clinical and Laboratory Standards Institute document M27M44S—Performance Standards for Antifungal Susceptibility Testing of Yeasts includes minimal inhibitory concentration, zone diameter, and quality control tables developed following the guidance in CLSI documents M27 and M44.(2) The data in the tables are valid only when the methodologies in CLSI documents M27 and M44 are followed. Users should replace previously published tables with these new tables. Changes in the tables since the previous edition was published appear in boldface type.

Overview of Changes

This document replaces the previous edition of the approved document, M60-Ed2, published in 2020. Several changes were made in this edition.

M27M44SEd3E
978-1-68440-163-5
40
Additional Details

The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.

Authors
Gary W. Procop, MD, MS
Philippe J. Dufresne, PhD, RMCCM
Elizabeth Berkow, PhD
Sharon K. Cullen, BS, RAC
Tanis Dingle, PhD, D(ABMM), FCCM
Jeff Fuller, PhD, FCCM, D(ABMM)
Kimberly E. Hanson, MD, MHS
Nicole M. Holliday, BA
Audrey N. Schuetz, MD, MPH, D(ABMM)
Paul E. Verweij, MD, FECMM
Nathan P. Wiederhold, PharmD
Adrian M. Zelazny, PhD, D(ABMM)